HomeB6E • FRA
add
Swedish Orphan Biovitrum AB (publ)
Previous close
€36.60
Day range
€37.16 - €37.16
Year range
€22.40 - €37.16
Market cap
141.54B SEK
Avg Volume
86.00
P/E ratio
-
Dividend yield
-
Primary exchange
STO
Market news
Financials
Income Statement
Revenue
Net income
| (SEK) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 7.82B | 5.19% |
Operating expense | 3.84B | -7.91% |
Net income | 1.86B | 33.21% |
Net profit margin | 23.79 | 26.61% |
Earnings per share | 5.65 | 41.96% |
EBITDA | 3.22B | 37.27% |
Effective tax rate | 14.24% | — |
Balance Sheet
Total assets
Total liabilities
| (SEK) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.04B | -8.68% |
Total assets | 67.43B | -10.62% |
Total liabilities | 29.71B | -15.47% |
Total equity | 37.72B | — |
Shares outstanding | 345.66M | — |
Price to book | 0.34 | — |
Return on assets | 9.17% | — |
Return on capital | 12.48% | — |
Cash Flow
Net change in cash
| (SEK) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | 1.86B | 33.21% |
Cash from operations | 2.98B | 65.89% |
Cash from investing | -1.08B | -966.34% |
Cash from financing | -1.90B | -65.13% |
Net change in cash | 2.00M | -99.63% |
Free cash flow | 2.43B | -16.30% |
About
Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden.
In 2020 it had a revenue of SEK 15.261 billion and 1,509 employees. Wikipedia
Founded
1939
Website
Employees
1,888
